Testing effectiveness (Phase 2)Study completedNCT00240929
What this trial is testing
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
Who this might be right for
-Unhealthy Children With a History of Prematurity
MedImmune LLC 150